Rafarma Pharmaceuticals (RAFA) Financial Statements
Rafarma Pharmaceuticals Financial Overview
Rafarma Pharmaceuticals's market cap is currently $1.45M. The company's EPS TTM is $0.00; its P/E ratio is 7.39; Rafarma Pharmaceuticals has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 9.18M | $ 9.08M | $ 10.13M | $ 64.31M | $ 77.41M |
| Gross Profit | $ 761.00K | $ 674.00K | $ 600.00K | $ 22.81M | $ 27.27M |
| Operating Income | $ 489.00K | $ 405.00K | $ 313.00K | $ 7.15M | $ 14.72M |
| EBITDA | $ 489.00K | $ 342.00K | $ 526.89K | $ 6.45M | $ 14.72M |
| Net Income | $ 349.00K | $ 266.00K | $ 273.00K | $ 4.96M | $ 11.57M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 58.00K | $ 77.00K | $ 66.00K | $ 18.83M | $ 13.62M |
| Total Assets | $ 11.99M | $ 12.03M | $ 12.16M | $ 98.32M | $ 89.34M |
| Total Debt | $ 23.00K | $ 0.00 | $ 0.00 | $ 909.00K | $ 1.70M |
| Net Debt | $ -35.00K | $ -77.00K | $ -66.00K | $ -17.14M | $ -11.89M |
| Total Liabilities | $ 1.49M | $ 1.65M | $ 1.65M | $ 20.43M | $ 19.84M |
| Stockholders' Equity | $ 10.50M | $ 10.38M | $ 10.51M | $ 77.89M | $ 69.51M |
| Cash Flow | |||||
| Free Cash Flow | $ -16.00K | $ 44.00K | $ 0.00 | $ 6.69M | $ 2.88M |
| Operating Cash Flow | $ 112.00K | $ 44.00K | $ -50.67M | $ 18.77M | $ 2.88M |
| Investing Cash Flow | $ -128.00K | $ 2.00K | $ 32.90M | $ -11.72M | $ 6.86M |
| Financing Cash Flow | $ -3.00K | $ -50.00K | $ -197.00K | $ -2.59M | $ -5.28M |
Currency in USD
